Frazier Management as of March 31, 2021
Portfolio Holdings for Frazier Management
Frazier Management holds 35 positions in its portfolio as reported in the March 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics (ARQT) | 24.5 | $305M | 11M | 28.93 | |
| Phathom Pharmaceuticals (PHAT) | 17.6 | $219M | 5.8M | 37.56 | |
| Passage Bio (PASG) | 7.0 | $88M | 5.0M | 17.48 | |
| Mirum Pharmaceuticals (MIRM) | 5.7 | $71M | 3.6M | 19.82 | |
| Krystal Biotech (KRYS) | 5.5 | $69M | 895k | 77.04 | |
| Tarsus Pharmaceuticals (TARS) | 5.0 | $62M | 1.9M | 32.23 | |
| Vaxcyte (PCVX) | 3.7 | $46M | 2.3M | 19.75 | |
| Iovance Biotherapeutics (IOVA) | 3.3 | $42M | 1.3M | 31.66 | |
| Translate Bio | 2.9 | $36M | 2.2M | 16.49 | |
| Trillium Therapeutics Com New | 2.7 | $33M | 3.1M | 10.70 | |
| Syndax Pharmaceuticals (SNDX) | 2.6 | $32M | 1.4M | 22.36 | |
| Alpine Immune Sciences | 2.2 | $27M | 2.6M | 10.60 | |
| Sutro Biopharma (STRO) | 1.8 | $23M | 1.0M | 22.76 | |
| Anaptysbio Inc Common (ANAB) | 1.6 | $19M | 900k | 21.55 | |
| Aclaris Therapeutics (ACRS) | 1.4 | $18M | 696k | 25.20 | |
| Molecular Templates | 1.4 | $17M | 1.4M | 12.62 | |
| Iveric Bio | 1.3 | $16M | 2.5M | 6.18 | |
| Frazier Lifesciences Acqu Unit 12/09/2025 | 1.2 | $15M | 1.5M | 10.16 | |
| Adverum Biotechnologies | 1.1 | $14M | 1.4M | 9.86 | |
| Regenxbio Inc equity us cm (RGNX) | 1.0 | $12M | 352k | 34.11 | |
| Gritstone Oncology Ord (GRTS) | 0.8 | $9.7M | 1.0M | 9.43 | |
| Aptinyx | 0.8 | $9.6M | 3.2M | 3.00 | |
| Essa Pharma Com New (EPIX) | 0.7 | $9.2M | 317k | 29.05 | |
| Immunovant (IMVT) | 0.7 | $8.1M | 508k | 16.04 | |
| Scholar Rock Hldg Corp (SRRK) | 0.6 | $7.9M | 156k | 50.66 | |
| Freeline Therapeutics Hldgs Sponsored Ads | 0.5 | $6.8M | 550k | 12.30 | |
| Epizyme | 0.5 | $6.4M | 739k | 8.71 | |
| Avadel Pharmaceuticals Sponsored Adr | 0.4 | $5.2M | 578k | 9.04 | |
| Bellus Health Com New | 0.4 | $4.9M | 1.3M | 3.82 | |
| Allena Pharmaceuticals | 0.4 | $4.6M | 3.3M | 1.39 | |
| Sierra Oncology Com New | 0.3 | $3.5M | 203k | 17.23 | |
| Cardiff Oncology (CRDF) | 0.2 | $2.7M | 294k | 9.26 | |
| Iterum Therapeutics SHS | 0.2 | $2.2M | 1.5M | 1.41 | |
| Galera Therapeutics (GRTX) | 0.2 | $2.1M | 241k | 8.82 | |
| Nabriva Therapeutics SHS | 0.1 | $707k | 426k | 1.66 |
